Significant Ownership of Baselake Partners, LP
- Signature - Title
- /s/ David Paolella - David Paolella, Managing Member of Baselake Management, LLC, its investment manager
- Location
- Troy, MI
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Baselake Partners, LP.
Follow Filing Activity
Follow Baselake Partners, LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of Baselake Partners, LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| SYBX | Synlogic, Inc. | Common Stock, par value $0.001 per share | 9.7% | $1,265,400 | 1,140,000 | Baselake Partners, LP | 20 Jan 2026 | ||
| TXMD | TherapeuticsMD, Inc. | Common Stock, par value $0.001 per share | 5.2% | $1,384,373 | 607,181 | Baselake Partners, LP | 30 Mar 2026 | ||
| NEUP | Neuphoria Therapeutics Inc. | Common Stock, $0.00001 par value per share | 4.1% | $862,110 | 222,222 | 0% | Baselake Partners, LP | 31 Dec 2025 | |
| ATHA | LeonaBio, Inc. f.k.a. Athira Pharma, Inc. | Common Stock, $0.0001 par value per share | 1.9% | $573,723 | -$921,208 | 75,789 | -62% | Baselake Partners, LP | 31 Dec 2025 |
| GBIO | Generation Bio Co. | Common Stock, $0.0001 Par Value | 0% | $0 | -$1,918,000 | 0 | -100% | Baselake Partners, LP | 09 Feb 2026 |
| KZR | Kezar Life Sciences, Inc. | Common Stock, $0.001 par value per share | 0% | 0 | -100% | Baselake Partners, LP | 11 May 2026 |
Schedules 13D/G Reported by Baselake Partners, LP:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.